Abstract:Abstract Background Chronic cerebral hypoperfusion (CCH) is the leading cause of cerebral small vessel disease (CSVD). CCH is strongly associated with blood–brain barrier (BBB) dysfunction and white matter lesions (WMLs) in CSVD. However, the effects of CCH on BBB integrity and components and the cellular and molecular mechanisms underlying the effects of BBB dysfunction remain elusive. Whether maintaining BBB integrity can reverse CCH-induced brain damage has also not been explored. Methods In this study, we established a rat model of CSVD via permanent bilateral common carotid artery occlusion (2VO) to mimic the chronic hypoperfusive state of CSVD. The progression of BBB dysfunction and components of the BBB were assessed using immunostaining, Western blotting, transmission electron microscopy (TEM) and RNA sequencing. We also observed the protective role of imatinib, a tyrosine kinase inhibitor, on BBB integrity and neuroprotective function following CCH. The data were analyzed using one-way or two-way ANOVA. Results We noted transient yet severe breakdown of the BBB in the corpus callosum (CC) following CCH. The BBB was severely impaired as early as 1 day postoperation and most severely impaired 3 days postoperation. BBB breakdown preceded neuroinflammatory responses and the formation of WMLs. Moreover, pericyte loss was associated with BBB impairment, and the accumulation of serum protein was mediated by increased endothelial transcytosis in the CC. RNA sequencing also revealed increased transcytosis genes expression. BBB dysfunction led to brain damage through regulation of TGF-β/Smad2 signaling. Furthermore, imatinib treatment ameliorated serum protein leakage, oligodendrocyte progenitor cell (OPC) activation, endothelial transcytosis, microglial activation, and aberrant TGF-β/Smad2 signaling activation. Conclusions Our results indicate that reduced pericyte coverage leads to increased BBB permeability via endothelial transcytosis. Imatinib executes a protective role on the BBB integrity via inhibition of endothelial transcytosis. Maintenance of BBB integrity ameliorates brain damage through regulation of TGF-β/Smad2 signaling following CCH; therefore, reversal of BBB dysfunction may be a promising strategy for CSVD treatment.

Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders

Targeting Pericytes for Therapeutic Approaches to Neurological Disorders

Pericytes for Therapeutic Approaches to Ischemic Stroke

Pericytes in Cerebrovascular Diseases: an Emerging Therapeutic Target.

Pericytes in Brain Injury and Repair after Ischemic Stroke.

Transplantation of hPSC-derived pericyte-like cells promotes functional recovery in ischemic stroke mice

Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier

The myeloid cell-driven transdifferentiation of endothelial cells into pericytes promotes the restoration of BBB function and brain self-repair after stroke

Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases

Pericytes regulate the blood–brain barrier

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

Single-Cell Analysis of Blood-Brain Barrier Response to Pericyte Loss

Recent advances in tissue repair of the blood-brain barrier after stroke

Stem Cell Therapy for Neurodegenerative Diseases: How Do Stem Cells Bypass the Blood-Brain Barrier and Home to the Brain?

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Regenerative Therapies for Central Nervous System Diseases: a Biomaterials Approach

Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells

Application and advances of biomimetic membrane materials in central nervous system disorders

The blood–brain barrier: structure, regulation, and drug delivery

The Blood Brain Barrier in Cerebral Ischemic Injury – Disruption and Repair

Reduction in Pericyte Coverage Leads to Blood–brain Barrier Dysfunction Via Endothelial Transcytosis Following Chronic Cerebral Hypoperfusion